AXIM® Biotechnologies (OTCMKTS: AXIM) Acquires a Diagnostic Testing of Dry Eye Disease from Advanced Tear Diagnostics, LLC

Dry Eye Disease (DED) impacts increase with age and can significantly impair quality of life and visual acuity. The condition occurs when a person’s tears are not able to provide adequate lubrication for the eyes. Studies indicate that more than 20 million people suffer from Dry Eye Disease, whose symptoms are still under investigation. However, as that happens,  AXIM® Biotechnologies (OTCMKTS: AXIM) has stepped to bring a lasting solution for Dry Eye Disease.

Through a Definitive Agreement and a Binding Term Sheet, the research and development company has partnered with Advanced Tear Diagnostics, LLC. The move will facilitate the acquisition of the technology for testing DED, two FDA authorizations, and commercialization approval of two ophthalmic diagnostic lab tests.

The Tests are Part of a Highly Specialized Point-of-Care Lab System

Dry Eye Disease is multifactorial with so many disparate causes. Hence diagnosing it is sometimes a challenge. Different stages present different symptoms, plus there is always a discordance between signs and symptoms. 

However, the acquisition of the tests is expected to help eye-care physicians detect and quantify a variety of disorders. The tests are part of a highly specialized point-of-care (POC) lab testing system. The system is one of its kind, given that it is the first point-of-care lab testing system across the globe to receive FDA clearance. The second is for the measurement of Ocular Immunoglobulin E (IgE). 

“…this technology acquisition gives AXIM two finished tests that are cleared by the FDA and we are now in the process of creating an aggressive marketing and sales plan…,” CEO of AXIM® Biotech John W. Huemoeller II clarified. 

The Introduction of the ELISA Test

Today, there are six common variants of the SARS-CoV-2 virus, and those from Brazil, South Africa, California, and Britain are reportedly more infectious. This has prompted the development of a new test to measure levels of immune protection against the six variants. The ELISA test developed by AXIM is a standard immunoassay in diagnostic and research labs. It is sensitive but straightforward and can be automated. According to Huemoeller II, the test is also capable of valuable information to vaccine companies on the quality of their vaccines in the protection against SARS-CoV-2 variants.